​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences stock forecast is as follows: an average price target of $15.50 (represents a 33.97% upside from ROIV’s last price of $11.57) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

ROIV Price Target

The average price target for Roivant Sciences (ROIV) is $15.50 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $12.50. This represents a potential 33.97% upside from ROIV's last price of $11.57.

ROIV Analyst Ratings

Buy

According to 10 Wall Street analysts, Roivant Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ROIV stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Roivant Sciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David RisingerLeerink Partners$17.00$11.9242.62%46.93%
Sep 19, 2024Corinne JenkinsGoldman Sachs$17.00$12.0541.02%46.93%
Sep 11, 2024Chi FongBank of America Securities$12.50$12.460.36%8.04%
May 31, 2024Allison BratzelPiper Sandler$20.00$10.3992.49%72.86%
Apr 03, 2024Douglas TsaoH.C. Wainwright$18.00$10.9264.84%55.57%
Apr 03, 2024Neena Bitritto-GargDeutsche Bank$15.00$10.9237.36%29.65%
Apr 02, 2024Corinne JenkinsGoldman Sachs$18.00$10.9264.84%55.57%
Mar 13, 2024Corinne JenkinsGoldman Sachs$16.00$10.6250.66%38.29%
Jan 05, 2023Citigroup$14.00$7.5685.19%21.00%
Dec 19, 2022Leerink Partners$10.00$7.3236.61%-13.57%
Aug 18, 2022Citigroup$10.00$4.04147.52%-13.57%
May 24, 2022Goldman Sachs$12.00$3.86210.88%3.72%

The latest Roivant Sciences stock forecast, released on Oct 21, 2024 by David Risinger from Leerink Partners, set a price target of $17.00, which represents a 42.62% increase from the stock price at the time of the forecast ($11.92), and a 46.93% increase from ROIV last price ($11.57).

Roivant Sciences Price Target by Period

1M3M12M
# Anlaysts-28
Avg Price Target-$17.00$16.69
Last Closing Price$11.57$11.57$11.57
Upside/Downside-100.00%46.93%44.25%

In the current month, the average price target of Roivant Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Roivant Sciences's last price of $11.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Leerink PartnersOutperformOutperformHold
Sep 19, 2024Goldman SachsBuyBuyHold
Sep 11, 2024H.C. WainwrightUnderperformUnderperformHold
Sep 11, 2024Piper SandlerBuyBuyHold
Sep 11, 2024Cowen & Co.BuyBuyHold
Sep 11, 2024H.C. WainwrightBuyBuyHold
Sep 11, 2024Bank of America SecuritiesNeutralNeutralHold
Jul 10, 2024Piper SandlerOverweightOverweightHold
May 31, 2024Goldman SachsUnderperformUnderperformHold
May 31, 2024H.C. WainwrightBuyBuyHold
May 31, 2024Piper SandlerOverweightOverweightHold
May 30, 2024Cantor FitzgeraldOverweightOverweightHold
Apr 03, 2024H.C. WainwrightBuyBuyHold
Apr 03, 2024Deutsche BankBuyBuyHold
Apr 02, 2024Goldman SachsBuyBuyHold
Mar 25, 2024Wolfe ResearchBuyBuyHold
Jun 29, 2023Goldman SachsBuyBuyHold
Jan 05, 2023CitigroupBuyBuyHold
Dec 19, 2022SVB LeerinkOutperformOutperformHold
Nov 15, 2022SVB LeerinkOutperformOutperformHold
Aug 18, 2022CitigroupBuyBuyHold
May 24, 2022Goldman SachsBuyBuyHold
Apr 29, 2022Cantor FitzgeraldOverweightInitialise

Roivant Sciences's last stock rating was published by Leerink Partners on Oct 21, 2024. The company gave ROIV a "Outperform" rating, the same as its previous rate.

Roivant Sciences Financial Forecast

Roivant Sciences Revenue Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 21
Revenue-------------$37.14M$18.42M-$27.38M$17.05M$13.99M
Avg Forecast$40.00M$38.00M$6.00M$6.00M$3.90M$3.90M$3.90M$41.40M$23.95M$8.14M$45.92M$30.72M$31.01M$31.77M$27.11M$24.49M$18.17M$14.78M$7.22M
High Forecast$40.00M$38.00M$6.00M$6.00M$10.07M$10.07M$10.07M$106.87M$61.82M$15.44M$118.54M$30.72M$31.05M$38.53M$47.69M$63.21M$46.90M$38.14M$7.22M
Low Forecast$40.00M$38.00M$6.00M$6.00M$544.19K$544.19K$544.19K$5.78M$3.34M$1.29M$6.41M$30.72M$30.96M$25.41M$21.06M$3.42M$2.54M$2.06M$7.22M
# Analysts3333211144233696437
Surprise %-------------1.17%0.68%-1.51%1.15%1.94%

Roivant Sciences's average Quarter revenue forecast for Mar 24 based on 3 analysts is $31.01M, with a low forecast of $30.96M, and a high forecast of $31.05M. ROIV's average Quarter revenue forecast represents a -16.51% decrease compared to the company's last Quarter revenue of $37.14M (Dec 23).

Roivant Sciences EBITDA Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 21
# Analysts3333211144233696437
EBITDA-------------$-224.78M$-276.45M-$-203.10M$-221.04M$-1.16B
Avg Forecast$-24.00M$-22.80M$-3.60M$-3.60M$-2.34M$-2.34M$-2.34M$-24.84M$-14.37M$-4.89M$-27.55M$-18.43M$-18.60M$-19.06M$-16.26M$-14.69M$-10.90M$-8.87M$-4.33M
High Forecast$-24.00M$-22.80M$-3.60M$-3.60M$-326.51K$-326.51K$-326.51K$-3.47M$-2.00M$-771.83K$-3.84M$-18.43M$-18.58M$-15.24M$-12.63M$-2.05M$-1.52M$-1.24M$-4.33M
Low Forecast$-24.00M$-22.80M$-3.60M$-3.60M$-6.04M$-6.04M$-6.04M$-64.12M$-37.09M$-9.26M$-71.13M$-18.43M$-18.63M$-23.12M$-28.62M$-37.93M$-28.14M$-22.89M$-4.33M
Surprise %-------------11.79%17.00%-18.63%24.93%267.79%

undefined analysts predict ROIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Roivant Sciences's previous annual EBITDA (undefined) of $NaN.

Roivant Sciences Net Income Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 21
# Analysts3333211144233696437
Net Income-------------$5.10B$-304.33M-$-175.42M$-384.90M$-225.64M
Avg Forecast$-250.12M$-242.30M$-257.94M$-250.12M$-242.71M$-205.93M$-196.13M$-154.45M$-164.56M$-185.71M$-181.66M$-178.96M$-194.42M$-227.26M$-211.82M$-208.38M$-265.77M$-290.13M$-254.11M
High Forecast$-250.12M$-242.30M$-257.94M$-250.12M$28.79M$24.42M$23.26M$18.32M$-157.08M$-123.80M$21.55M$21.23M$23.06M$-176.76M$-157.16M$24.71M$31.52M$34.41M$-254.11M
Low Forecast$-250.12M$-242.30M$-257.94M$-250.12M$-741.66M$-629.29M$-599.33M$-471.97M$-179.52M$-255.35M$-555.13M$-546.87M$-594.11M$-252.51M$-232.31M$-636.77M$-812.14M$-886.58M$-254.11M
Surprise %--------------22.42%1.44%-0.66%1.33%0.89%

Roivant Sciences's average Quarter net income forecast for Mar 24 is $-194.42M, with a range of $-594.11M to $23.06M. ROIV's average Quarter net income forecast represents a -103.82% decrease compared to the company's last Quarter net income of $5.10B (Dec 23).

Roivant Sciences SG&A Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 21
# Analysts3333211144233696437
SG&A-------------$197.28M$164.35M-$125.51M$168.26M$437.78M
Avg Forecast$361.67M$343.58M$54.25M$54.25M$35.19M$35.19M$35.19M$373.50M$216.05M$73.46M$414.30M$277.14M$279.75M$286.65M$244.54M$220.91M$163.90M$133.31M$65.30M
High Forecast$361.67M$343.58M$54.25M$54.25M$90.83M$90.83M$90.83M$964.16M$557.72M$139.27M$1.07B$277.15M$280.15M$347.60M$430.30M$570.27M$423.10M$344.13M$65.30M
Low Forecast$361.67M$343.58M$54.25M$54.25M$4.91M$4.91M$4.91M$52.12M$30.15M$11.61M$57.81M$277.14M$279.34M$229.22M$189.98M$30.83M$22.87M$18.60M$65.30M
Surprise %-------------0.69%0.67%-0.77%1.26%6.70%

Roivant Sciences's average Quarter SG&A projection for Mar 24 is $279.75M, based on 3 Wall Street analysts, with a range of $279.34M to $280.15M. The forecast indicates a 41.80% rise compared to ROIV last annual SG&A of $197.28M (Dec 23).

Roivant Sciences EPS Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 21
# Analysts3333211144233696437
EPS-------------$6.37$-0.40-$-0.24$-0.54$-0.33
Avg Forecast$-0.32$-0.31$-0.33$-0.32$-0.33$-0.28$-0.27$-0.21$-0.22$-0.25$-0.25$-0.24$-0.26$-0.31$-0.29$-0.28$-0.36$-0.39$-0.33
High Forecast$-0.32$-0.31$-0.33$-0.32$0.04$0.03$0.03$0.02$-0.21$-0.17$0.03$0.03$0.03$-0.24$-0.21$0.03$0.04$0.05$-0.33
Low Forecast$-0.32$-0.31$-0.33$-0.32$-1.01$-0.86$-0.81$-0.64$-0.24$-0.35$-0.75$-0.74$-0.81$-0.34$-0.32$-0.87$-1.10$-1.21$-0.33
Surprise %--------------20.61%1.39%-0.66%1.37%1.02%

According to 3 Wall Street analysts, Roivant Sciences's projected average Quarter EPS for Mar 24 is $-0.26, with a low estimate of $-0.81 and a high estimate of $0.03. This represents a -104.15% decrease compared to ROIV previous annual EPS of $6.37 (Dec 23).

Roivant Sciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INZYInozyme Pharma$2.94$16.00444.22%Buy
CGEMCullinan Oncology$11.49$34.00195.91%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
PHATPhathom Pharmaceuticals$8.37$20.00138.95%Buy
SNDXSyndax Pharmaceuticals$13.63$31.67132.36%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
ASNDAscendis Pharma$140.30$211.1450.49%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
ROIVRoivant Sciences$12.15$15.5027.57%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
VRDNViridian Therapeutics$20.82$22.759.27%Buy

ROIV Forecast FAQ

Is Roivant Sciences a good buy?

Yes, according to 10 Wall Street analysts, Roivant Sciences (ROIV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of ROIV's total ratings.

What is ROIV's price target?

Roivant Sciences (ROIV) average price target is $15.5 with a range of $12.5 to $17, implying a 33.97% from its last price of $11.57. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Roivant Sciences stock go up soon?

According to Wall Street analysts' prediction for ROIV stock, the company can go up by 33.97% (from the last price of $11.57 to the average price target of $15.5), up by 46.93% based on the highest stock price target, and up by 8.04% based on the lowest stock price target.

Can Roivant Sciences stock reach $20?

ROIV's average twelve months analyst stock price target of $15.5 does not support the claim that Roivant Sciences can reach $20 in the near future.

What are Roivant Sciences's analysts' financial forecasts?

Roivant Sciences's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $53.1M (high $137.07M, low $7.41M), average EBITDA is $-31.86M (high $-4.446M, low $-82.243M), average net income is $-799M (high $94.79M, low $-2.442B), average SG&A $479.06M (high $1.24B, low $66.85M), and average EPS is $-1.087 (high $0.129, low $-3.321). ROIV's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $90M (high $90M, low $90M), average EBITDA is $-54M (high $-54M, low $-54M), average net income is $-1B (high $-1B, low $-1B), average SG&A $813.75M (high $813.75M, low $813.75M), and average EPS is $-1.28 (high $-1.28, low $-1.28).

Did the ROIV's actual financial results beat the analysts' financial forecasts?

Based on Roivant Sciences's last annual report (Mar 2023), the company's revenue was $28.01M, which missed the average analysts forecast of $32.94M by -14.97%. Apple's EBITDA was $-1.175B, beating the average prediction of $-19.766M by 5846.03%. The company's net income was $-1.23B, beating the average estimation of $-556M by 121.27%. Apple's SG&A was $600.51M, beating the average forecast of $297.22M by 102.04%. Lastly, the company's EPS was $-1.73, beating the average prediction of $-0.756 by 128.88%. In terms of the last quarterly report (Dec 2023), Roivant Sciences's revenue was $37.14M, beating the average analysts' forecast of $31.77M by 16.89%. The company's EBITDA was $-225M, beating the average prediction of $-19.064M by 1079.06%. Roivant Sciences's net income was $5.1B, missing the average estimation of $-227M by -2342.44%. The company's SG&A was $197.28M, missing the average forecast of $286.65M by -31.18%. Lastly, the company's EPS was $6.37, missing the average prediction of $-0.309 by -2161.49%